Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, January 12th. The shares were sold at an average price of $45.00, for a total transaction of $495,000.00. Following the transaction, the senior vice president now directly owns 35,701 shares in the company, valued at approximately $1,606,545. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Christopher Rovaldi also recently made the following trade(s):

  • On Wednesday, January 3rd, Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock. The shares were sold at an average price of $42.42, for a total transaction of $96,123.72.

Shares of Acceleron Pharma Inc (NASDAQ XLRN) traded down $0.03 during trading on Wednesday, hitting $44.99. 372,194 shares of the stock traded hands, compared to its average volume of 360,200. The firm has a market capitalization of $1,980.00, a P/E ratio of -17.44 and a beta of 1.59. Acceleron Pharma Inc has a twelve month low of $23.07 and a twelve month high of $46.93.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.02. The business had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. Acceleron Pharma’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the company posted ($0.55) earnings per share. analysts expect that Acceleron Pharma Inc will post -2.65 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its stake in Acceleron Pharma by 11.1% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 175,553 shares of the biopharmaceutical company’s stock worth $7,451,000 after buying an additional 17,601 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Acceleron Pharma during the third quarter worth $1,496,000. Iguana Healthcare Management LLC acquired a new stake in Acceleron Pharma during the third quarter worth $2,612,000. Point72 Asset Management L.P. acquired a new stake in Acceleron Pharma during the third quarter worth $2,721,000. Finally, Granahan Investment Management Inc. MA boosted its stake in Acceleron Pharma by 15.2% during the third quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock worth $8,102,000 after buying an additional 28,694 shares in the last quarter. Institutional investors and hedge funds own 85.70% of the company’s stock.

A number of research firms have recently commented on XLRN. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. ValuEngine lowered shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Finally, HC Wainwright lifted their price target on shares of Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $44.56.

WARNING: “Christopher Rovaldi Sells 11,000 Shares of Acceleron Pharma Inc (XLRN) Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/christopher-rovaldi-sells-11000-shares-of-acceleron-pharma-inc-xlrn-stock.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.